AgomAb Therapeutics (NASDAQ:AGMB) Coverage Initiated by Analysts at Cantor Fitzgerald

Equities researchers at Cantor Fitzgerald initiated coverage on shares of AgomAb Therapeutics (NASDAQ:AGMB) in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm set an “overweight” rating on the stock.

Several other equities research analysts have also issued reports on AGMB. Wall Street Zen lowered shares of AgomAb Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. HC Wainwright started coverage on shares of AgomAb Therapeutics in a report on Monday, June 22nd. They set a “buy” rating and a $35.00 price target for the company. Finally, B. Riley Financial assumed coverage on AgomAb Therapeutics in a research report on Thursday, July 23rd. They set a “buy” rating and a $34.00 price objective on the stock. Six investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, AgomAb Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $33.00.

AgomAb Therapeutics Price Performance

Shares of AGMB opened at $13.73 on Wednesday. The company’s 50 day moving average price is $12.67. AgomAb Therapeutics has a one year low of $8.75 and a one year high of $17.82.

AgomAb Therapeutics (NASDAQ:AGMB) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.46) EPS for the quarter. On average, sell-side analysts anticipate that AgomAb Therapeutics will post -1.77 earnings per share for the current fiscal year.

AgomAb Therapeutics Company Profile

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.